Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz And Polpharma Strike Global Deal For Natalizumab

Executive Summary

Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.

You may also be interested in...



Gan & Lee Insulins Data Is Boon For Sandoz

Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.

Bourdage Sets Out Sandoz’ Biosimilar Growth Ambitions

Sandoz plans to add at least one new molecule per year to its biosimilar development plans, while still maintaining a “selective” approach to targets, head of biopharmaceuticals Pierre Bourdage explains in the second part of an exclusive interview with Generics Bulletin.

Polpharma Simplifies Structure By Absorbing Subsidiaries

Poland’s Polpharma SA has absorbed subsidiaries Polpharma BH and Medana Pharma as part of the group’s efforts to simplify management structures and processes and increase operational efficiency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;